Please visit answersincme.com/860/2026-MC-001665-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ajai Chari, MD; Caitlin Costello, MD; and Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO. In this activity, experts in multiple myeloma (MM) discuss the therapeutic rationale, clinical data, and practical integration of subcutaneous anti-CD38 therapies to optimize care for patients with MM. Upon completion of this activity, participants should be better able to: Recognize the rationale for using subcutaneous (SC) formulations of anti-CD38 monoclonal antibodies in patients with multiple myeloma (MM); Assess the clinical profiles of approved and emerging SC formulations of anti-CD38 monoclonal antibodies in patients with MM; and Outline evidence-based, patient-centered strategies for optimizing outcomes with SC formulations of anti-CD38 monoclonal antibodies in patients with MM.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related